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Abstract. Alzheimer’s disease is a disease which cannot be cured completely. In this aspect ribonucleic acid interference
(RNAi) therapy is a prospective therapeutic mechanism which can be used for identifying a future curative procedure. RNAi
therapy comprises small interfering RNA (siRNA), short hairpin (shRNA) and micro-RNA therapeutics. Within these three
mechanisms we have identified two of them as an effective method of combating this genetic incurable disease. siRNAs and
shRNAs are very much effective in vitro that is already proved in many research work. In our study we have used a very potent,
biocompatible nanoparticle-layered double hydroxide for delivering these macromolecules. However, the intercalation and
cellular internalization of these macromolecules demonstrated significant differences. As siRNAs have low-molecular weight
than shRNAs they demonstrated different characteristics in the case of internalization within layered-double hydroxide and
while cellular internalization. At the end of this study it has been found that both of these macromolecules may be used as
a therapeutic approach of Alzheimer’s disease after studying it in future in animal and human subjects.
Keywords. siRNA; shRNA; layered-double hydroxide; Alzheimer’s disease; RNAi therapy.
1. Introduction
Layered-double hydroxide (LDH) is currently well-known
anionic clay for multiple uses [1–5]. The general formula
of this nanoparticle is [M2+(1−x) M
3+
x (OH)]An−(x/n) · mH2O, in
which M2+ is a bivalent cation, M3+ is a trivalent cation and
A is a anion with valence of n. Mg Al–LDH has a close resem-
blance with brucite. Brucites have the octahedral positively
charged layers and in between these layers there are negatively
charged anions. These anions can be readily exchanged by any
other anions in the media. The process is known as the ion-
exchange method. There are several types of inorganic and
biomolecules which are used for this ion-exchange method,
among them different types of drugs [6–8] and genetic mate-
rials [7,9–11] are included.
High biocompatibility [12], easily available precursors for
synthesis, cationic in nature [13], high-loading capacity [14]
and low cost [15] make LDH an excellent delivery vehicle.
Moreover, the mechanism of intercalation within the lay-
ers provides a protective shield [16] and controls the release
mechanism [17] of the loaded particle. Although LDH with
its intercalation produces a stable configuration of the host
molecule, however, in the presence of more electronegative
ions in the environment it can lead to ion exchange which on
the other hand helps to improve targeting and release within
the cell [18].
The biomolecules which can be intercalated within the
LDH layers include deoxyribonucleic acids (DNAs) and
ribonucleic acids (RNAs). The major difference between a
DNA and RNA is at the 2′-hydroxyl (2′-OH) group which
plays the pivotal role in the RNA structure and function. Sim-
ilar to A, B or Z DNA, RNA also comprises diverse structures
like hairpin-loop RNA, linear-duplex RNA, etc. [19,20]. The
RNA world hypothesis discussed about the RNA molecules
which can work as a catalyst in addition to carry genetic infor-
mation [21]. The deep hydrothermal vents are considered to
be the source of primitive RNA molecules though it remains a
question that at that high temperature and pressure how these
molecules remained intact. The possible explanation of this
query is that the clay-like particles similar to LDH may have
protected the RNA molecules which are highly fragile.
Small-interfering RNAs (siRNAs) are the double-stranded
RNAs which have a significant role in RNA-interference
(RNAi) therapy. As from the name it can be stated that it is
smaller in structure compared to other types of RNAs. Only
20–25 base pairs are enough for preparing a synthetic siRNA
[22]. Another type of RNA is short-hairpin RNAs (shRNAs)
comprises hairpin loops in their structure. Expression of this
type of RNA can be accomplished by the delivery of a plasmid
or viral or bacterial vector [23]. These types of RNAs are not
naturally available in the body of an organism rather they are
synthesized externally and can be used for several therapeutic
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procedures. However, the main drawback of this therapeutic
measure is bare siRNAs or shRNAs which cannot be used
in the body of an organism as they can be easily degraded
in the blood flow due to the presence of several RNase
enzymes in the blood. When the RNAs are solely inserted,
it is impermeable through the cell membrane and it can pro-
duce immunogenic reactions in the blood vascular system. To
overcome this problem nanoparticles help to a large extent.
The most used RNAi therapy can be mediated by both
chemically synthesized siRNA and plasmid-based shRNA.
Although both of these molecules produce similar functional
outcomes but they have some basic differences. The first draw-
back of siRNAs is their short life within the target cells. It has
been found that siRNAs accumulate within the cell for 4 h and
then they become plateau [24]. The kinetics of siRNA inter-
ference peaks were observed at around 24–48 h. As opposed
to siRNA, shRNAs have a long-lasting effect as the delivery
plasmids of these RNAs are integrated in the host genome
and in the nucleus of the cell and transported to the cytoplasm
[25]. The fluorescent-tagged siRNA study demonstrated high
degradability and turnover of this type of RNA. On the other
hand, shRNAs can be continuously synthesized within the
host cell so much more durable than the former.
The next important difference between these two types of
RNAs is that siRNAs are chemically synthesized and require-
ment of complex structures makes them expensive. On the
other hand, in the case of shRNAs making modifications is
difficult as the same relies on the host machinery of the expres-
sion vector [26–28].
However, due to their structural and functional implications
the shRNAs are found to be more potent in gene silencing than
siRNAs. Although in the case of dosage manipulation siRNAs
are found to be better than shRNAs.
Both siRNA and shRNAs have several advantages and dis-
advantages from mechanical point of view. In this study, we
are intended to find out the differences between these two
most important RNAs when they are intercalated within the
LDH nanoparticle.
2. Experimental
2.1 siRNA intercalation in LDH
The amyloid precursor protein (APP) siRNA sense strand
sequence corresponds to 5′-AAGUGAAGAUGGAUGCAGA
AUUC-3′ (Dharmacon). The siRNA and Mg2Al(OH)6NO3–
LDH nanoparticles were mixed in various mass ratios ranging
from 1:10 to 1:60 and deionized water was added to a final
volume of 10 μl, maintaining the final siRNA concentration
constant at 0.1 μg μl−1. Samples were incubated at 37◦C for
30 min after which an appropriate amount of RNA-loading
buffer was added to each sample. Gel electrophoresis of sam-
ples was carried out on 3% agarose gels (TBE buffer, 1%
ethidium bromide) at 80 V for 45 min and gels were subse-
quently imaged using a Biorad Gel Documentation System.
2.2 Isolation of plasmid from Escherichia coli
Following the autoclaving of 2.5% LB broth medium, ampi-
cillin was added to a final concentration of 100 μg ml−1, and
then E. coli transfected with the TRIPZ Inducible Lentivi-
ral shRNA plasmid (M/S DharmaconTM GIPZTM Lentivi-
ral shRNA GE Healthcare, UK) was added and cultured
overnight at 37◦C with mild shaking. The plasmid was iso-
lated using a Geneaid High-Speed Plasmid Mini Kit, Geneaid
Biotech, Taiwan, according to the manufacturer’s protocol,
followed by the quantification of its amount by measuring
absorption of the solution at 260 nm, and confirmation of the
identity, purity and amount using the gel retardation assay.
2.3 Intercalation of shRNA-plasmid in LDH nanoparticles
A suspension of the LDH nanoparticles was prepared in
DNase-free water at a final concentration of 10 mg ml−1,
and mixed with the shRNA-plasmid (200 ng μl−1) with the
shRNA-plasmid:LDH mass ratios of 1:12.5, 1:25, 1:50 and
1:75, followed by incubation for different periods at 37◦C for
inducing the intercalation to form a shRNA-plasmid–LDH
nanoconjugate. 0.7% agarose gel containing ethidium bro-
mide was prepared, and the loaded samples containing 0.1 μg
of the shRNA plasmid and DNA loading buffer were elec-
trophoresed in TBE buffer containing ethidium bromide at
80 V for 45 h. The bare plasmid was used as the control and
the gel images were captured using a UV transilluminator
(M/S Bio-Rad, Philadelphia, PA, USA).
2.4 Cell culture
The SH-SY5Y cell line (neuroblastoma) procured from
NCCS, Pune was cultured under laboratory conditions.
RPMI-1640 media (AL-162S, HIMEDIA) supplemented
with 10% fetal bovine serum and 1% antibiotic were used
for the culture of the cells. The cells were kept at 37◦C and
5% CO2.
2.4a Fluorescence-activated cell sorting (FACS) analysis:
For flowcytometry, cells were seeded in a six well plate
at 1 × 106 cells per well. The cells were treated with 10
and 20 μg of intercalated-fluorescein isothiocyanate (FITC)
tagged siRNAs or green fluorescent protein (GFP)-tagged
shRNAs per 2.5 ml media. The cells were incubated for
24 h. After 24 h, the cells were centrifuged and the pellet
was washed three times with phosphate-buffered saline (PBS)
and subjected to flowcytometry in FACS VERSE (BD bio-
sciences, US). For the time-dependent study the cells were
plated as before and treated with 10 μg of intercalated-FITC
tagged siRNAs or GFP-tagged shRNAs per 2.5 ml of media
for 6, 12 and 18 h. After incubation the cells were centrifuged
and washed with PBS as before and subjected to flowcytom-
etry analysis in FACS VERSE (BD biosciences, US).
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2.5 Enzyme-linked immunosorbent assay (ELISA)
(a) SH-SY5Y cells were stably transfected by Lipofec-
tamine 2000 with the vector containing the full-length
APP695 isoform as a wild-type (APP wild-type). After
this the APP siRNA–LDH or shRNA–LDH conjugate
was used for the treatment of the cell line at the previous
optimized concentration for 24 h.
Figure 1. (a) Gel retardation assay of siRNA intercalation into
LDH nanoparticles. Lane 1: ladder; Lane 2: bare siRNA; Lanes 3–8:
siRNA:LDH at the mass ratios of 1:35, 1:40, 1:45, 1:50, 1:55 and 1:60
at 37◦C. (b) Gel retardation image of shRNA-plasmid intercalation
into LDH nanoparticles. Lane 1: 1 Kb ladder; Lane 2: bare plasmid
(11.8 Kb); Lane 3: 1:30; Lane 4: 1:40; Lane 5: 1:50; Lane 6: 1:60;
Lane 7: 1:70 and Lane 8: 1:80 in a mass ratio of plasmid:LDH, post
2 h incubation at 37◦C.
(b) Secreted Aβ42 was measured in cell culture medium
samples using a human Aβ42 ELISA kit (Thermo
Fisher Scientific, Cat. #KHB3441) in cells plated at
an equal density in triplicates. A standard curve was
generated by linear regression analysis and used to cal-
culate the amount of Aβ42 in each sample.
3. Results
3.1 Intercalation
siRNA having the complimentary sequence of the APP gene
mRNA was used in this study. We have used specifically the
siRNA from Dharmacon for our work. Similarly Dharmacon
shRNA-plasmid specific for the APP gene was used. For inter-
calation, different siRNA:LDH mass ratios were used from
1:35 to 1:60 and incubated at 37◦C for 1 h and then subjected
to agarose gel electrophoresis. The intercalation is more when
the presence of LDH is more, in a 1:50 mass ratio the total
siRNA was intercalated. A 50-fold increased amount of LDH
is sufficient to retain the siRNA in the gel electrophoresis
well (figure 1a). Similarly shRNA was incubated with LDH
at 37◦C using shRNA:LDH mass ratios of 1:30 to 1:80. It was
observed that complete intercalation of shRNA was traced at
a mass ratio of 1:70 after 2 h of incubation, when the mass
of the nanoparticles was 70-fold over the mass of the plas-
mid, leading to complete conjugation (figure 1b). These data
demonstrated a distinct difference between the intercalation of
Figure 2. Flowcytometry of cellular internalization of the FITC–siRNA/LDH conjugate at different concentrations by
the SH-SY5Y cell line. (a) Control, (b) 10 μg siRNA–500 μg LDH and (c) 20 μg siRNA–1000 μg LDH. Concentration-
dependent cellular internalization of shRNA–LDH, (d) control, (e) 10 μg ml−1 and (f) 20 μg ml−1 indicating the
percentage cellular uptake.
   10 Page 4 of 5 Bull. Mater. Sci.           (2020) 43:10 
siRNA and shRNA of the APP gene. As the molecular weight
of siRNA is lower than the molecular weight of the shRNA
it is prominent that higher the molecular weight greater the
time required for intercalation within the LDH layers.
Figure 3. Flowcytometry of cellular internalization of the FITC–
siRNA/LDH conjugate at different time points by the SH-SY5Y
cell line. (a) Control, (b) 6 h, (c) 12 h and (d) 18 h. Time-dependent
cellular internalization of shRNA–LDH (e) control, (f) 12 h, (g) 24 h
and (h) 48 h indicating the percentage cellular uptake.
3.2 Cellular internalization depending on concentration
The siRNA/shRNA sequence of the APP gene which we
have used does not correspond with any other human gene
sequences. So, we have investigated the cellular uptake of
the FITC-tagged siRNA/LDH and GFP-tagged shRNA–LDH
conjugate in the SH-SY5Y cell line. For this purpose, the SH-
SY5Y cells were seeded in a six well plate and treated with
the siRNA/LDH or shRNA–LDH conjugate with the previous
concentration as mentioned before. After 24 h incubation, the
cells were subjected to FACS analysis.
As demonstrated in figure 2, the FITC-APP-siRNA/LDH
conjugate was efficiently internalized by the SH-SY5Y cells.
A total of 39.3% cells were found to be FITC positive after
treatment with the siRNA/LDH conjugate for 24 h. Similarly,
25.32% cellular uptake was found in the case of the GFP-
shRNA–LDH nanoconjugate (figure 2).
So, it is demonstrated that as the molecular weight of siRNA
is low that is why the cellular internalization is greater in
the case of the same, on the other hand as the shRNAs have
the higher-molecular weight their cellular uptake is compar-
atively low.
3.3 Cellular internalization in a time-dependent manner
To find out the approximate time required to internalize the
APP siRNA/LDH conjugate the next experiment was con-
ducted. For this purpose the SH-SY5Y cells were seeded as
before in six well plates and treated with various concentra-
tions of the conjugate at different time points e.g., 6, 12 and
18 h. However, at 6 h the FITC–siRNA/LDH conjugates
showed 64.73% uptake which is maximum in 24 h study
by the cells (figure 3). It can be said that after 6 h the cell
released the fluorescence and demonstrated lesser extent of
fluorescence intensity.
Similarly, in the case of shRNA the maximum uptake is
found at 24 h and also it is lower than siRNA which is 26.23%
after 24 h (figure 3). So, it is confirm that shRNA takes a
longer time than siRNA for cellular uptake. Moreover, the
Figure 4. (a) APP level after treatment with siRNA and (b) APP level after treatment with shRNA.
‘C’ denotes control, ‘W’ denotes wild type and others indicate the incubation time.
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uptake percentage after 6 h in the case of siRNA is also very
higher than the shRNA–LDH nanoconjugate.
3.4 ELISA for the quantification of extracellular APP
We measured Aβ42 levels by ELISA in medium collected
from cells expressing endogenous APP or overexpressing
APP wild-type (figure 4). As expected, cells overexpress-
ing APP wild-type secrete more Aβ42 compared to control
cells. Moreover, after treatment with the siRNA–LDH and
shRNA–LDH was also checked by ELISA analysis and
it also demonstrated a significant amount of reduction in
the expression of the APP protein level with a p value
<0.05.
4. Discussion and conclusion
In conclusion the basic difference of siRNA and shRNA inter-
calated within LDH is their molecular weight. Due to these
differences the time of intercalation is more, the release kinet-
ics is different, the optimum concentration of internalization
within the cells is different and the time for cellular uptake
is also greater in the case of shRNA. Moreover, the ELISA
results showed that shRNAs have a long standing effect com-
pared to siRNA.
Finally, it can be concluded that shRNA is a more potent
therapeutic agent than siRNA although in some cases siRNA
can be used. siRNAs are dose specific; short time requirement
of gene therapy can be achieved using siRNA but to achieve
long term effect shRNAs are the better option.
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